



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/643,196

Filing Date

August 18, 2003

First Named Inventor

Edmund J. MORAN

Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket Number

P-156-US2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
cl	A1	US-4,894,219	01-16-1990	Baker et al.	
	A2	US-5,750,701	05-12-1998	Beeley et al.	
	A3	US-6,265,581 B1	07-24-2001	Bell et al.	
	A4	US-6,541,669 B1	04-01-2003	Moran et al.	
	A5	US-6,576,793 B1	06-10-2003	Moran et al.	
cl	A6	US-2002/0022625 A1	02-21-2002	Walland et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² - Number ⁴ - Kind Code ⁵ (if known)				
cl	B1	WO 95/25104 A1	09-21-1995	Smithkline Beecham P.L.C.		
	B2	WO 00/75114 A1	12-14-2000	Novartis AG		
	B3	WO 01/07026 A2	02-01-2001	Eli Lilly and Co.		
	B4	WO 01/35947 A2	05-25-2001	Eli Lilly and Co.		
	B5	WO 01/83462 A1 (in German) with English abstract	11-08-2001	Boehringer Ingelheim Pharma KG		
cl	B6	WO 02/38544 A2	05-16-2002	Eli Lilly and Co.		
	B7	EP 0 147 719	07-10-1985	Tanabe Seiyaku Co., Ltd.		
	B8	BE 849.794 (in French) with English abstract	4-15-1977	Otsuka Pharmaceutical Co., Ltd.		
cl	B9	JP 52-83379 (in Japanese) with English abstract	7-12-1977	Otsuka Pharmaceutical Co., Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
cl	C1	DEYRUP et al., "Structure-affinity profile of 8-hydroxycarboxtyril-based agonists that dissociate slowly from the β_2 -adrenoceptor", Naunyn-Schmiedeberg's Arch Pharmacol, Vol. 359: pp 168-177 (1999)	
	C2	ISOGAYA et al., "Binding Pockets of the β_1 - and β_2 -Adrenergic Receptors for Subtype-Selective Agonists", Molecular Pharmacology, Vol. 56, pp 875-885 (1999)	
	C3	MILECKI et al., "Carboxtyril Derivatives Having Potent β -Adrenergic Agonist Properties", Vol. 30, pp 1563-1566, 1987	
cl	C4	YOSHIZAKI et al., "Sympathomimetic Amines Having a Carboxtyril Nucleus", Vol. 19, No. 9, pp 1138-1142 (1976)	

Examiner
Signature

Date

Considered

1/10/05

PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.